Moreover, using the atherosclerosis model ApoE−/− mouse, the NLRP3 inflammasome emerges as a central target in the fight against ED and CVDs, as evidenced by recent studies highlighting various therapeutic strategies. This evidence concerns the gene NLRP3 and atherosclerosis.